<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014469</url>
  </required_header>
  <id_info>
    <org_study_id>00-126</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>P01CA023766</secondary_id>
    <secondary_id>MSKCC-00126</secondary_id>
    <secondary_id>NCI-H01-0070</secondary_id>
    <nct_id>NCT00014469</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer</brief_title>
  <official_title>A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with bone marrow transplantation may
      allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of busulfan and melphalan followed by
      donor bone marrow transplantation in treating patients who have advanced hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antileukemic potential of busulfan and melphalan prior to allogeneic bone
           marrow transplantation in patients with advanced or high-risk hematologic malignancy.

        -  Determine the incidence of transplantation-related morbidity and mortality in patients
           treated with this regimen.

        -  Determine the incidence of acute and chronic graft-versus-host disease in patients
           treated with this regimen.

      OUTLINE: Patients receive cytoreductive chemotherapy comprising busulfan IV over 2 hours
      every 6 hours for a total of 16 doses on days -8 to -5 and melphalan IV over 30 minutes on
      days -4 to -2. Patients undergo T-cell replete allogeneic bone marrow transplantation on day
      0. For graft-versus-host disease prophylaxis, patients receive tacrolimus IV continuously or
      every 12 hours beginning on day -1 and continuing for 50 days to 6 months followed by a
      taper. Once oral medications are tolerated, patients switch to oral tacrolimus every 12
      hours. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

      Patients are followed weekly through day 100, every 6 weeks for 3 months, every 3 months for
      1 year, and then every 3-6 months for 6 months.

      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following:

               -  Infant leukemia

               -  Acute lymphoblastic leukemia in 3rd or greater remission or relapse

               -  Undifferentiated or biphenotypic leukemia in 2nd or greater remission or relapse

               -  Juvenile chronic myelogenous leukemia (CML)

               -  Acute myelogenous leukemia (AML) in 3rd or greater remission or relapse

               -  Primary advanced myelodysplastic syndrome (MDS) excluding refractory anemia (RA)
                  and RA with ringed sideroblasts

               -  Therapy-related MDS of any stage or AML

               -  CML in 2nd or greater chronic phase, accelerated, or blastic phase

               -  Acute leukemia, CML, or MDS but unable to tolerate total body irradiation (TBI)
                  due to potential neurotoxicity (prior TBI, prior local radiotherapy,or under 2
                  years of age)

          -  No active CNS disease

          -  Related or unrelated bone marrow donor matched at HLA-A, B, and DR beta 1

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 60 (over 60 considered on case-by-case basis)

        Performance status:

          -  Karnofsky 70-100%

          -  Lansky 70-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  AST and ALT less than 2 times upper limit of normal

          -  Bilirubin less than 1.5 mg/dL unless liver is involved with disease

        Renal:

          -  Creatinine normal

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular:

          -  Asymptomatic with no prior risk factors OR

          -  LVEF greater than 50% if symptomatic

        Pulmonary:

          -  Asymptomatic with no prior risk factors OR

          -  Diffusion capacity greater than 50% predicted (corrected for hemoglobin) if
             symptomatic

        Other:

          -  No active uncontrolled viral, bacterial, or fungal infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  More than 6 months since prior allogeneic or autologous stem cell transplantation

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trudy N. Small, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

